Boots has launched a private medical cannabis service in the UK, marking a significant development for an industry that has largely been served by specialist clinics since medical cannabis prescribing became legal in 2018.
Announced on 16 November 2026, the new service, called SureLeaf, will offer eligible patients access to specialist consultations, prescriptions where clinically appropriate and ongoing care through Boots Online Doctor.
The arrival of one of Britain’s best-known healthcare brands raises an important question: what could this mean for patients, existing medical cannabis clinics and the future of treatment in the UK?
Boots has entered the UK medical cannabis market with SureLeaf, a private healthcare service delivered through Boots Online Doctor.
The service is designed for eligible adults living with certain chronic pain conditions, generalised anxiety disorder or insomnia who have not achieved adequate relief from conventional treatments.
According to the official Boots announcement, SureLeaf combines specialist medical consultations with multidisciplinary clinical oversight and ongoing patient monitoring.
Although the launch brings medical cannabis into the services offered by a familiar high-street healthcare brand, treatment will be accessed privately through its online doctor platform. It does not mean patients can obtain medical cannabis over the counter at Boots pharmacies.
SureLeaf follows a specialist assessment process, with prescriptions only issued where treatment is considered clinically appropriate.
Patients begin by completing an online assessment. Their information is reviewed by the clinical team before they can progress to a video consultation with a consultant on the General Medical Council’s Specialist Register.
Any proposed prescription must then undergo an independent review by a multidisciplinary clinical team, including a second consultant.
Patients who begin treatment receive an initial review after 28 days, followed by further reviews at least every three months. These appointments help clinicians monitor symptoms, treatment effectiveness and potential side effects.
This approach reflects an important principle of medical cannabis prescribing: treatment requires individual clinical assessment and ongoing oversight, rather than simply choosing a product.
SureLeaf is available to patients aged 25 and over who meet its clinical eligibility criteria.
Boots has identified three main areas of treatment:
Patients must also have previously tried conventional treatment options without achieving adequate symptom relief. Meeting these initial requirements does not guarantee a prescription.
Eligibility requirements can differ between private clinics. Anyone considering treatment should review the criteria of their chosen provider and discuss their medical history with an appropriately qualified clinician.
Boots’ SureLeaf service is private, meaning patients pay for access to treatment rather than receiving it through the NHS.
At launch, the service has been reported as offering an annual plan costing £99, covering an initial assessment and four follow-up consultations. Medication and additional appointments are charged separately.
A one-month trial option costing £89 has also been reported, including an assessment, a 10ml starter quantity of cannabis oil and a follow-up check-in.
These are launch prices and may change. Patients should check the latest Boots service information and confirm what is included before proceeding.
Boots entering the medical cannabis market could be an important step towards greater public awareness and recognition of cannabis-based medicines as a legitimate area of specialist healthcare.
Medical cannabis has been legally available on prescription in the UK since November 2018. However, awareness of the legal prescribing framework remains uneven, and many patients are still unfamiliar with the private treatment pathway.
The involvement of a nationally recognised healthcare retailer may encourage more people to learn about the difference between recreational cannabis and prescribed cannabis-based medicines.
For many patients, Boots is a familiar name associated with pharmacies, prescriptions and everyday healthcare.
Its entry into the sector could help bring medical cannabis into more mainstream conversations about long-term healthcare. However, increased awareness should not be confused with evidence that treatment is suitable or effective for everyone.
The UK already has a growing number of specialist private medical cannabis clinics. Boots’ arrival introduces another provider for eligible patients to consider.
As the market develops, patients may increasingly compare clinics based on clinical expertise, eligibility requirements, consultation fees, medication costs, follow-up arrangements and the quality of ongoing support.
The growth of medical cannabis prescribing also brings greater attention to patient safety and clinical governance.
The General Pharmaceutical Council’s report on pharmacies supplying cannabis-based medicinal products highlights the importance of appropriate safeguards in this developing area of healthcare.
Alongside SureLeaf, Boots has announced that it is exploring a medical cannabis research collaboration with the University of Nottingham.
The proposed programme would examine patient outcomes, prescribing practices and experiences of medical cannabis treatment for chronic pain.
This could contribute to the growing body of real-world evidence surrounding medical cannabis. However, the collaboration is still being explored, and no new study findings have been announced as part of the launch.
Further high-quality research remains important. Although some patients report improvements with prescribed cannabis-based medicines, the strength of clinical evidence varies between conditions, and potential risks must be considered alongside possible benefits.
For patients, the most immediate change is the arrival of another private specialist service offering medical cannabis assessments.
However, the underlying legal framework remains the same. Cannabis-based products for medicinal use can be prescribed by appropriately qualified specialist doctors where clinically appropriate.
Access through the NHS remains limited. The NHS guidance on medical cannabis explains the circumstances in which cannabis-based medicines may be prescribed and the limitations of the current evidence.
Patients considering private treatment should understand the full costs, clinical assessment process and arrangements for ongoing care before choosing a provider.
At CB1 Medical, we provide specialist medical cannabis assessments through a UK-wide telehealth service. Our approach focuses on individual clinical suitability, appropriate prescribing and continued patient support.
Yes. Boots launched SureLeaf on 16 November 2026, offering eligible patients access to private specialist assessments and medical cannabis prescriptions where clinically appropriate.
No. SureLeaf operates through Boots Online Doctor. Medical cannabis remains a prescription-only treatment requiring specialist clinical assessment.
No. SureLeaf is a private healthcare service. Patients pay for the relevant service and treatment costs, subject to the provider’s terms.
Yes. Certain cannabis-based medicines have been legally available through specialist prescribing since November 2018. Recreational cannabis remains illegal.
The launch gives eligible patients another private treatment pathway and may increase awareness of medical cannabis. However, it does not change NHS prescribing rules or remove the need for specialist assessment.
Boots’ entry into the medical cannabis market represents an important development for a sector that has grown steadily since the 2018 prescribing changes.
Its arrival could help improve public understanding, encourage greater choice and bring further attention to the importance of clinical standards and research.
For patients, the central message remains unchanged: medical cannabis is a specialist treatment that should be considered carefully, with appropriate medical advice and ongoing clinical support. As more providers enter the market, clear information and responsible prescribing will remain essential.